Direct and label-free monitoring of albumin in 2D fatty liver disease model using plasmonic nanogratings

dc.contributor.authorLópez Muñoz, Gerardo A.
dc.contributor.authorOrtega, María Alejandra
dc.contributor.authorFerret-Miñana, Ainhoa
dc.contributor.authorDe Chiara, Francesco
dc.contributor.authorAzcón, Javier Ramón
dc.date.accessioned2021-02-10T15:28:25Z
dc.date.available2021-02-10T15:28:25Z
dc.date.issued2020-12-15
dc.descriptionReproducció del document publicat a: https://doi.org/10.3390/nano10122520ca
dc.description.abstractNon-alcoholic fatty liver (NAFLD) is a metabolic disorder related to a chronic lipid accumulation within the hepatocytes. This disease is the most common liver disorder worldwide, and it is estimated that it is present in up to 25% of the world’s population. However, the real prevalence of this disease and the associated disorders is unknown mainly because reliable and applicable diagnostic tools are lacking. It is known that the level of albumin, a pleiotropic protein synthesized by hepatocytes, is correlated with the correct function of the liver. The development of a complementary tool that allows direct, sensitive, and label-free monitoring of albumin secretion in hepatocyte cell culture can provide insight into NAFLD’s mechanism and drug action. With this aim, we have developed a simple integrated plasmonic biosensor based on gold nanogratings from periodic nanostructures present in commercial Blu-ray optical discs. This sensor allows the direct and label-free monitoring of albumin in a 2D fatty liver disease model under flow conditions using a highly-specific polyclonal antibody. This technology avoids both the amplification and blocking steps showing a limit of detection within pM range (≈0.26 ng/mL). Thanks to this technology, we identified the optimal fetal bovine serum (FBS) concentration to maximize the cells’ lipid accumulation. Moreover, we discovered that the hepatocytes increased the amount of albumin secreted on the third day from the lipids challenge. These data demonstrate the ability of hepatocytes to respond to the lipid stimulation releasing more albumin. Further investigation is needed to unveil the biological significance of that cell behavior.ca
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid33334062
dc.identifier.urihttps://hdl.handle.net/2445/173821
dc.language.isoengca
dc.relation.ispartofNanomaterials, 2020, vol. 10, num. 12
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/714317/EU//DAMOCca
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/863037/EU//BLOC
dc.relation.urihttps://doi.org/10.3390/nano10122520
dc.rightscc by (c) López Muñoz et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
dc.subject.classificationMalalties del fetge
dc.subject.classificationCèl·lules hepàtiques
dc.subject.classificationMaterials nanoestructurats
dc.subject.otherLiver diseases
dc.subject.otherLiver cells
dc.subject.otherNanostructured materials
dc.titleDirect and label-free monitoring of albumin in 2D fatty liver disease model using plasmonic nanogratingsca
dc.typeinfo:eu-repo/semantics/articleca

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
L25_2020_Nanomaterials_10_2520_OA.pdfv3.pdf
Mida:
24.87 MB
Format:
Adobe Portable Document Format